Entresto vs Repatha
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Entresto | US Repatha | |
|---|---|---|
| Generic name | sacubitril/valsartan | evolocumab |
| Drug class | ARNI (Neprilysin Inhibitor + ARB) | PCSK9 Inhibitor (Biologic) |
| Treats | Chronic heart failure | High cholesterol, cardiovascular disease |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | Amgen |
| Year approved | 2015 | 2015 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | $120M |
| Common side effects | Low blood pressure, High potassium, Kidney problems, Dizziness | Injection site reactions, Allergic reactions, Back pain, Fatigue |
Frequently asked questions
Is Entresto or Repatha better?
Neither is universally "better." Entresto (sacubitril/valsartan) and Repatha (evolocumab) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Entresto and Repatha?
Entresto is a ARNI (Neprilysin Inhibitor + ARB) made by Novartis, while Repatha is a PCSK9 Inhibitor (Biologic) made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Entresto has the larger estimated TV advertising budget of the two.